Skip to main content
. Author manuscript; available in PMC: 2014 Dec 15.
Published in final edited form as: Clin Cancer Res. 2013 Oct 28;19(24):6967–6975. doi: 10.1158/1078-0432.CCR-12-1818

Figure 3.

Figure 3

Sorafenib sensitivity signature: (A) Scatter plot showing the correlation between Sorafenib signature and IC50 of sorafenib (rho = -0.71, P < 0.0001). (B) Kaplan-Meier curve for progression-free survival for the 37 patients with EGFR wild-type tumors and a high vs. low sorafenib sensitivity signature based on the median of the first principal component analysis.